The company has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc.
Natalie Carfora brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics, states Immunovia. She will take up her position on May 23, 2022.
“The hire of Natalie as Head of Market Access in the US is another key hire in-line with our strategic priority to strengthen our US team for a commercial scale up of IMMray PanCan-d in the US. Natalie will be instrumental in the pursuit of reimbursement coverage for IMMray PanCan-d in the US, the largest and most attractive diagnostic market globally in which Immunovia is commercializing its novel test since August last year,” says Philipp Mathieu, Acting CEO and President, Immunovia AB.
Read more: On the threshold of commercial launch
Natalie Carfora brings over ten years of sales and market access experience across biotechnology, medical device, and pharmaceutical industries to the team. Building partnerships through a variety of models across multiple channels including payers, pharmacy benefit managers, and specialty pharmacies, she is focused on optimizing patient care management. Natalie is a graduate of Boston University School of Management with a B.S. in Business Administration.
“Without precision medicine tools, patients suffer from late-stage diagnosis and poor prognosis. People at risk for pancreatic cancer need much better ways to detect cancer earlier. The IMMray PanCan-d test is a compelling clinical option for patients, providers, and payers. I am excited to partner with payers to offer IMMray PanCan-d access to their members, leading to improved clinical outcomes, increased patient satisfaction and cost of care savings,” says Natalie Carfora.